Small-Cell Lung Cancer: Treatment Progress and Prospects

ONCOLOGY

Volumn 12, Issue 5, 1998, Pages 647-658

  Clark, Romnee ^a   Ihde, Daniel C ^b  

^a Division of Medical Oncology   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IRINOTECAN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TOPOTECAN; VINCRISTINE;

CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; HUMAN; LUNG NODULE; LUNG SMALL CELL CANCER; NEUTROPENIA; PARANEOPLASTIC SYNDROME; REVIEW; SKULL IRRADIATION; SURVIVAL RATE; UNITED STATES;

ANTINEOPLASTIC AGENTS; CARCINOMA, SMALL CELL; HUMANS; PROGNOSIS; RISK FACTORS;

EID: 0031776001     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Parker SL, Tong T, Bolden S, et al: Cancer statistics. 1997. CA Cancer J Clin 47:5-27, 1997.
2. Samet JM: The epidemiology of lung cancer. Chest 103:205-298, 1993.
3. Travis WD, Lubin J, Ries L, et al: United States lung carcinoma incidence trends: Declining for most histologic types among males, increasing among females. Cancer 77:2464-2470, 1996
4. Parkin DM, Sankaranarayanan R: Over-view on small-cell lung cancer in the world. Anticancer Res 14:277-282, 1994.
5. Ernster VL: Female lung cancer. Annu Rev Public Health 17:97-114, 1996.
6. Steenland K, Loomis D, Shy C, et al: Review of occupational lung carcinogens. Am J Ind Med 29:474-490, 1996.
7. Gazdar A. The molecular and cellular basis of human lung cancer. Anticancer Res 13 261-268, 1994.
8. Bouchard C, Benhamou S, Dayer P: The effect of tobacco on lung cancer risk depends on CYP2D6 activity. Cancer Res 56:251-253, 1996.
9. Wiencke JK, Spitz MR, et al: Lung cancer in Mexican Americans and African Americans is associated with wild-type genotype of the NAD(P)H: Quinone oxireductase polymorphism. Cancer Epidemiol Biomarkers Prev 6127:87-92, 1997.
10. Williams CL: Basic science of small-cell lung cancer. Chest Surg Clin North Am 7:1-19, 1997.
11. Hirsch FR, Matthews MJ, Aisner S, et al: Histopathologic classification of small-cell lung cancer: Changing concepts and terminology. Cancer 62:973-977, 1988.
12. Patel AM, Peters SG: Clinical manifestations of lung cancer. Mayo Clin Proc 68:273-277, 1993.
13. Chute CG, Greenberg ER, Baton J, et al: Presenting conditions of 1539 population-based lung cancer patients by cell type and stage in New Hampshire and Vermont. Cancer 56:2107-2111, 1985.
14. Marchioli CC, Graziano SL: Paraneoplastic syndromes associated with small cell lung cancer. Chest Surg Clin North Am 7:65-80, 1997.
15. Patel AM, Davila DG, Peters SG: Paraneo-plastic syndromes associated with lung cancer. Mayo Clin Proc 68:278-287, 1993.
16. Ihde DC, Pass HI, Glatstein E: Small-cell cancer, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer Principles and Practice of Oncology, 5th ed, pp 911-949 Philadelphia, Lippencott-Raven, 1997.
17. Spiegelman D, Maurer LH, et al: Prognostic factors in small-cell carcinoma of the lung: An analysis of 1521 patients. J Clin Oncol 7:344-354, 1989.
18. Truong LD, Underwood RD, Greenberg SD, et al: Diagnosis and typing of lung carcinomas by cytopathologic methods: A review of 108 cases. Acta Cytol 29 379-383, 1985.
19. Arroliga AC, Matthay RA: The role of bronchoscopy in lung cancer. Clin Chest Med 14:87-95, 1993.
20. Karsell PR, McDougall JC: Diagnostic tests for lung cancer. Mayo Clin Proc 68:288-296, 1993
21. Salazar AM, Westcott JL: The role of transthoracic needle biopsy for the diagnosis and staging of lung cancer. Clin Chest Med 14:99-107, 1993.
22. Stahel RA, Ginsberg R, Havermann K, et al: Staging and prognostic factors in small cell lung cancer: A consensus report. Lung Cancer 5:119-126, 1989.
23. Livingston RB, McCracken JD, Trauth CJ, et al: Isolated pleural effusion in small-cell lung carcinoma: Favorable prognosis. Chest 81:208-211, 1982.
24. Albain KS, Crowley JJ, LeBlanc M, et al: Determinants of improved outcome in small-cell lung cancer: An analysis of the 2,580 patients Southwest Oncology Group data base. J Clin Oncol 8:1563-1574, 1990.
25. Richardson GE, Venzon DJ, Phelps R, et al: Application of an algorithm for staging small-cell lung cancer can save one-third of the initial evaluation costs. Arch Intern Med 153:329-337, 1993.
26. 18F-Fluorodeoxyglucose PET scans in lung cancer. Thorax 51:S16-S22, 1996.
27. Balaban EP, Walker BS, Cox JV, et al: Detection and staging of small-cell lung carcinoma with a technetium-labeled monoclonal antibody: A comparison with standard staging methods. Clin Nucl Med 17:439-445, 1992.
28. 111In]pentetreotide, a radiolabelled somatostatin analogue. Br J Cancer 69:762-766, 1994.
29. Berenger N, Moretti JL, Boaziz C, et al: Somatostatin receptor imaging in small-cell lung cancer. Eur J Cancer 32A:1429-1431, 1996
30. Fox W, Scadding JG: Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Lancer 2:63-65, 1973
31. Matthews MJ, Kanhouwa S, Pickren J, et al: Frequency of residual and metastatic tumor in patients undergoing curative surgical resection for lung cancer. Cancer Chemother Rep 4:63-67, 1973
32. Green RA, Humphrey E, Close H, et al: Alkylating agents in bronchogenic carcinoma Am J Med 46:516-525, 1969.
33. Bergsagel DE, Jenkin RDT, Pringle JF, et al: Lung cancer: Clinical trial of radiotherapy alone vs. radiotherapy plus cyclophosphamide. Cancer 30:621-627, 1972.
34. Hansen HH, Selawry OS, Simon R, et al: Combination chemotherapy of advanced lung cancer. Cancer 38:2201-2207, 1976.
35. Lowenbraun S, Bartolucci A, Smalley RV, et al: The superiority of combination chemotherapy over single-agent chemotherapy in small-cell lung carcinoma. Cancer 44:406-413, 1979.
36. Livingston RB, Moore TN, Heilbrun L, et al: Small-cell carcinoma of the lung: Combined chemotherapy and radiation. Ann Intern Med 88:194-199, 1978.
37. Evans WK, Osoba D, Feld R, et al: Etoposide (VP-16) and cisplatin. An effective treatment for relapse in small-cell lung cancer. J Clin Oncol 3:65-71, 1985.
38. Evans WK, Shepherd FA, Feld R, et al: VP-16 and cisplatin as first-Sine therapy for small cell lung cancer. J Clin Oncol 3:1471-1477, 1985.
39. Goldie JH, Coldman AJ, Gudauskas GA: Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 66:439-449, 1982
40. Evans WK, Feld R, Murray N, et al: Superiority of alternating non-cross-resistant chemotherapy in extensive small-cell lung cancer. Ann Intern Med 107:451-458, 1987.
41. Fukuoka M, Furuse K, Saijo N, et al: Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83:855-861, 1991.
42. Roth BJ, Johnson DH, Einhorn LH, et al: Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10:282-291, 1992.
43. Johnson DH, Einhorn LH, Birch R, et al: A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group J Clin Oncol 5:1731-1738, 1987.
44. Ihde DC, Mulshine JL, Kramer BS, et al: Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 12:2022-2034, 1994.
45. Einhorn LH, Crawford J, Birch R, et al: Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer. J Clin Oncol 6:451-456, 1988.
46. Ihde DC, Deisseroth AB, Lichter AS, et al: Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer. J Clin Oncol 4:1443-1454, 1986.
47. Humblet Y, Symann M, Bosley A, et al: Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: A randomized study. J Clin Oncol 5:1864-1873, 1987.
48. Souhami RL, Hajichristou HT, Miles DW, et al: Intensive chemotherapy with autologous bone marrow transplantation for small-cell lung cancer. Cancer Chemother Pharmacol 24:321-325, 1989.
49. Crawford J, Ozer H, Stoller R, et al: Re duction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164-170, 1991.
50. Hamm J, Schiller JH, Cuffie C, et al: Dose-ranging study of recombinant human granulo-cyte-macrophage colony-stimulating factor in small-cell lung carcinoma. J Clin Oncol 12:2667-2676, 1994.
51. Woll PJ, Hodgetts J, Lomax L, et al: Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol 13:652-659, 1995.
52. Savarese DMF, Hsieh CC, Stewart FM: Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors J Clin Oncol 15:2981-2995, 1997.
53. Bunn PA Jr. Carney DN: Overview of chemotherapy for small-cell lung cancer. Semin Oncol 24:57-69-57-74, 1997.
54. Cormier Y, Eisenhauer E, Muldal A, et al: Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). Ann Oncol 5:283-285, 1994.
55. Raßmann I, Thodtmann R, Depenbrock H, et al: Gemcitabine and etoposide in small-cell lung cancer: Phase I and II trials. Semin Oncol 24:S7-75-S7-78, 1997.
56. Ettinger DS: Single-agent paclitaxel in the treatment of small-cell lung cancer. Semin Oncol 23:S16:16-17, 1996.
57. Bunn PA Jr, Kelly K: Phase I study of cisplatin, etoposide, and paclitaxel in patients with extensive-stage small cell lung cancer: A University of Colorado Cancer Center study. Semin Oncol 23:516:11-15, 1996.
58. Greco FA, Hainsworth JD: Paclitaxel, carboplatin, and oral etoposide in the treatment of small-cell lung cancer. Semin Oncol 23:S16:7-10, 1996.
59. Smyth JF, Smith IE, Sessa C, et al: Activity of docetaxel (Taxotere) in small-cell lung cancer. Eur J Cancer 30A:1058-1060, 1994
60. Kaufmann SH: Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 51:1129-1136, 1991
61. Perez-Soler R, Glisson BS, Lee JS, et al: Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the to-poisomerase 1 poison topotecan. J Clin Oncol 14:2785-2790, 1996.
62. Ardizzoni A, Hansen H, Dombernowsky P, et al: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. J Clin Oncol 15:2090-2096, 1997.
63. Schiller JH, Kim KM, Hutson P, et al: Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: An Eastern Cooperative Oncology Group trial. J Clin Oncol 14:2345-2352, 1996.
64. Masuda N, Fukuoka M, Kusunoki Y, et al: CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992
65. Pignon JP, Arriagada R, Ihde DC, et al: A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327:1618-1624, 1992.
66. Williams TE, Turrisi AT: Role of radiotherapy in the treatment of small cell lung cancer. Chest Surg Clin North Am 7:135-149, 1997
67. Johnson DH, Kim K, Sause W, et al Cisplatin (P) & Etoposide (E) + thoracic radiotherapy (TRT) administered once or twice daily (BID) in limited stage (LS) small-cell lung cancer (SCLC): Final report of intergroup trial 0096. Proc Am Soc Clin Oncol 15:374, 1996.
68. Johnson DH, Turrisi AT, Chang AY, et al Alternating chemotherapy and twice-daily thoracic radiotherapy in limited-stage small-cell lung cancer. A pilot study of the Eastern Cooperative Oncology Group. J Clin Oncol 11:879-884, 1995.
69. Wagner H Jr: Prophylactic cranial irradiation for patients with small-cell lung cancer. Chest Surg Clin North Am 7:151-166, 1997.
70. Arriagada R, LeChevalier T, Bone F, et al: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst 87:183-190, 1995.
71. Urschel JD: Surgical treatment of peripheral small cell lung cancer. Chest Surg Clin North Am 7:95-103, 1997.